These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 10992199)

  • 1. Magnesium sulfate for tocolysis and risk of spastic cerebral palsy in premature children born to women without preeclampsia.
    Grether JK; Hoogstrate J; Walsh-Greene E; Nelson KB
    Am J Obstet Gynecol; 2000 Sep; 183(3):717-25. PubMed ID: 10992199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Can magnesium sulfate reduce the risk of cerebral palsy in very low birthweight infants?
    Nelson KB; Grether JK
    Pediatrics; 1995 Feb; 95(2):263-9. PubMed ID: 7838646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cerebral palsy in very low birth weight infants, pre-eclampsia and magnesium sulphate.
    Blair E; Palmer L; Stanley F
    Pediatrics; 1996 May; 97(5):780-2. PubMed ID: 8628635
    [No Abstract]   [Full Text] [Related]  

  • 4. Early neonatal hypotension in premature infants born to preeclamptic mothers.
    Teng RJ; Wu TJ; Sharma R; Garrison RD; Hudak ML
    J Perinatol; 2006 Aug; 26(8):471-5. PubMed ID: 16775620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intrapartum magnesium for prevention of cerebral palsy: continuing controversy?
    Cahill AG; Stout MJ; Caughey AB
    Curr Opin Obstet Gynecol; 2010 Apr; 22(2):122-7. PubMed ID: 20179596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An overview of the possible relationship between antenatal pharmacologic magnesium and cerebral palsy.
    Mittendorf R; Pryde PG
    J Perinat Med; 2000; 28(4):286-93. PubMed ID: 11031698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Magnesium sulfate tocolysis and risk of neonatal death.
    Grether JK; Hoogstrate J; Selvin S; Nelson KB
    Am J Obstet Gynecol; 1998 Jan; 178(1 Pt 1):1-6. PubMed ID: 9465794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Prevention of cerebral palsy using magnesium sulfate in pre-term newborns].
    Marret S; Chollat C; Levèque C; Marpeau L
    Arch Pediatr; 2011 Mar; 18(3):324-30. PubMed ID: 21257296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perinatal factors associated with cerebral palsy in children born in Sweden.
    Thorngren-Jerneck K; Herbst A
    Obstet Gynecol; 2006 Dec; 108(6):1499-505. PubMed ID: 17138786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of maternal magnesium sulfate treatment on newborns: a prospective controlled study.
    Riaz M; Porat R; Brodsky NL; Hurt H
    J Perinatol; 1998; 18(6 Pt 1):449-54. PubMed ID: 9848759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maternal obesity and neuroprotective magnesium sulfate.
    McPherson J; Smiley S; Stamilio D
    Am J Obstet Gynecol; 2015 Oct; 213(4):582.e1-6. PubMed ID: 26116874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A woman's own birth weight and gestational age predict her later risk of developing preeclampsia, a precursor of chronic disease.
    Innes KE; Marshall JA; Byers TE; Calonge N
    Epidemiology; 1999 Mar; 10(2):153-60. PubMed ID: 10069251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Possible antenatal and perinatal related factors in development of cystic periventricular leukomalacia.
    Murata Y; Itakura A; Matsuzawa K; Okumura A; Wakai K; Mizutani S
    Brain Dev; 2005 Jan; 27(1):17-21. PubMed ID: 15626536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short- and long-term outcomes in babies born after antenatal magnesium treatment.
    Mitani M; Matsuda Y; Shimada E;
    J Obstet Gynaecol Res; 2011 Nov; 37(11):1609-14. PubMed ID: 21733038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neonatal morbidity between 34 and 37 weeks' gestation.
    Fox MD; Allbert JR; McCaul JF; Martin RW; McLaughlin BN; Morrison JC
    J Perinatol; 1993; 13(5):349-53. PubMed ID: 8263618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antenatal and delivery risk factors and prevalence of cerebral palsy in Duzce (Turkey).
    Oztürk A; Demirci F; Yavuz T; Yildiz S; Değirmenci Y; Döşoğlu M; Avşar Y
    Brain Dev; 2007 Jan; 29(1):39-42. PubMed ID: 16824718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Why is there a modifying effect of gestational age on risk factors for cerebral palsy?
    Greenwood C; Yudkin P; Sellers S; Impey L; Doyle P
    Arch Dis Child Fetal Neonatal Ed; 2005 Mar; 90(2):F141-6. PubMed ID: 15724038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of maternal magnesium sulfate treatment on neonatal morbidity in < or = 1000-gram infants.
    Kimberlin DF; Hauth JC; Goldenberg RL; Bottoms SF; Iams JD; Mercer B; MacPherson C; Thurnau GR
    Am J Perinatol; 1998; 15(11):635-41. PubMed ID: 10064205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Feasibility of implementing magnesium sulphate for neuroprotection in a tertiary obstetric unit.
    Ow LL; Kennedy A; McCarthy EA; Walker SP
    Aust N Z J Obstet Gynaecol; 2012 Aug; 52(4):356-60. PubMed ID: 22515404
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effect of magnesium sulphate on mortality and neurologic morbidity of the very-preterm newborn (of less than 33 weeks) with two-year neurological outcome: results of the prospective PREMAG trial].
    Marret S; Marpeau L; Follet-Bouhamed C; Cambonie G; Astruc D; Delaporte B; Bruel H; Guillois B; Pinquier D; Zupan-Simunek V; Bénichou J;
    Gynecol Obstet Fertil; 2008 Mar; 36(3):278-88. PubMed ID: 18337147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.